🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

14 recruiting trials

for Mesothelin Positive Tumors

CT-95 in Advanced Cancers Associated With Mesothelin Expression NCT06756035Phase 19 sites📍 Denver📍 Chicago📍 Grand Rapids Context Therapeutics Inc. · Tests: CT-95 CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors NCT05410717Phase 11 site📍 Guangzhou Second Affiliated Hospital of Guangzhou Medical University · Tests: Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer or Malignant Peritoneal Mesothelioma NCT06623396Phase 17 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: M28z1XXPD1DNR CAR SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma NCT05568680Phase 15 sites📍 Tampa📍 Westwood📍 Philadelphia Verismo Therapeutics · Tests: SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors NCT07083323Phase 1, Phase 21 site📍 Beijing Sichuan Huiyu Pharmaceutical Co., Ltd · Tests: HY05350 for injection, HY05350 for injection Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors NCT07010523NA1 site📍 Hangzhou First Affiliated Hospital of Zhejiang University · Tests: Anti-mesothelin CAR-T cells, Fludarabine, Cyclophosphamide Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors NCT05141253EARLY Phase 11 site📍 Wuhan Tongji Hospital · Tests: RD133 An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors NCT05166070EARLY Phase 11 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: RD133 Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC NCT07510802Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: Dual-target CAR-NK cells, Lymphodepleting, Supportive care Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma NCT01950572n/a1 site📍 Bethesda National Cancer Institute (NCI) Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) NCT07486089Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: Dual-target CAR-NK cells (EB-DT-CAR-NK), Lymphodepleting chemotherapy, Supportive care A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer NCT06760364Phase 11 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: CHT102 A Clinical Study of CHT102 in Mesothelin Positive Advanced Solid Tumors NCT06717022NA1 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: CHT102 allogeneic CAR T cells Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma NCT06885697Phase 11 site📍 Bethesda National Cancer Institute (NCI) · Tests: cyclophosphamide, fludarabine, TNhYP218 CAR T Cells, mesothelin expression testing
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy